For more than 20 years Dan Curto has been focused on helping life sciences companies solve legal, compliance and regulatory challenges. 


From 1998 to 2012, Dan was a member of the international law firm of McDermott, Will & Emery. As a partner at McDermott, his practice focused on guiding life sciences companies through government investigations, litigation and compliance remediation. At McDermott, Dan was lead counsel for one of the biggest qui tam lawsuits that has been litigated in the District of Massachusetts.  As part of this work, Dan oversaw the defense of issues associated with payments to doctors, off-label sales, price reporting and GMP manufacturing issues.


In 2012, Dan moved in-house and until 2021 held various leadership positions at Sanofi, Biogen and BeiGene, including serving as global and US commercial counsel, leading a global investigation function that oversaw all internal compliance investigations and handled all government matters, and serving as the head of global litigation and enterprise risk management. 


Dan has been directly involved in managing the risk mitigation, compliance, investigation and defense of many of the Life Science industries biggest legal and compliance challenges, including:

  • Numerous government investigations and qui tam matters involving anti-kickback issues associated with payments to doctors and patients (speaker programs, consultant programs, discounting)

  • Off-label issues

  • Patient Services including use of nurse educators, reimbursement and billing assistance, co-pay issues, and patient care managers

  • Grants, sponsorships and charitable donations, including those made to HCPs and HCP groups, as well as grants to foundations that provide co-pay support

  • Pricing issues, including best price, AWP and AMP

  • Manufacturing issues, including issues involving GMP and billing/pricing issues related to vial fill

  • Research misconduct 

  • Data privacy and HIPAA concerns


Dan also has extensive experience assessing and improving global legal and compliance functions. He has managed Foreign Corrupt Practices Act issues throughout the world including in the EU, Asia, South America, India and the Middle East.  He has also worked closely with global affiliate and distributor legal and compliance teams to assess, build and run effective and efficient compliance programs.

Dan has been recognized numerous times as a rising star by Super Lawyers.  He regularly speaks and writes on topics related to the Life Sciences industry.  He attended Northeastern University ('95) and Harvard Law School ('98). 

Standing Photo_Dan_adobespark_edited.png